Tissue Inhibitor of Metalloproteinases-3 Peptides Inhibit Angiogenesis and Choroidal Neovascularization in Mice

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  Qi, Jian Hua ^a   Ebrahem, Quteba ^a   Ali, Mariya ^a   Cutler, Alecia ^a   Bell, Brent ^d   Prayson, Nicholas ^a   Sears, Jonathan ^a   Knauper, Vera ^b   Murphy, Gillian ^c   Anand Apte, Bela ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CARDIFF UNIVERSITY   (United Kingdom)

^c CANCER RESEARCH UK CAMBRIDGE RESEARCH INSTITUTE   (United Kingdom)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

SYNTHETIC PEPTIDE; TISSUE INHIBITOR OF METALLOPROTEINASE 3; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ARTICLE; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME ACTIVITY; IN VIVO STUDY; MOUSE; NONHUMAN; PEPTIDE SYNTHESIS; PHARMACOLOGICAL BLOCKING; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; RECEPTOR BINDING; SIGNAL TRANSDUCTION; STRUCTURE ANALYSIS; SUBRETINAL NEOVASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; BRUCH MEMBRANE; CELLS, CULTURED; CHOROIDAL NEOVASCULARIZATION; ENDOTHELIUM, VASCULAR; GENE EXPRESSION REGULATION; HUMANS; LASER COAGULATION; MICE; MICE, INBRED C57BL; PEPTIDES; PHOSPHORYLATION; SIGNAL TRANSDUCTION; SOLID-PHASE SYNTHESIS TECHNIQUES; TISSUE INHIBITOR OF METALLOPROTEINASE-3; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84874571743     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0055667     Document Type: Article

References (41)

1. Amour A, Knight CG, Webster A, Slocombe PM, Stephens PE, et al. (2000) The in vitro activity of ADAM-10 is inhibited by TIMP-1 and TIMP-3. FEBS Lett 473: 275-279.
2. Amour A, Slocombe PM, Webster A, Butler M, Knight CG, et al. (1998) TNF-alpha converting enzyme (TACE) is inhibited by TIMP-3. FEBS Lett 435: 39-44.
3. Hashimoto G, Aoki T, Nakamura H, Tanzawa K, Okada Y, (2001) Inhibition of ADAMTS4 (aggrecanase-1) by tissue inhibitors of metalloproteinases (TIMP-1, 2, 3 and 4). FEBS Lett 494: 192-195.
4. Jacobsen J, Visse R, Sorensen HP, Enghild JJ, Brew K, et al. (2008) Catalytic properties of ADAM12 and its domain deletion mutants. Biochemistry 47: 537-547.
5. Kashiwagi M, Tortorella M, Nagase H, Brew K, (2001) TIMP-3 is a potent inhibitor of aggrecanase 1 (ADAM-TS4) and aggrecanase 2 (ADAM-TS5). J Biol Chem 276: 12501-12504.
6. Wang WM, Ge G, Lim NH, Nagase H, Greenspan DS, (2006) TIMP-3 inhibits the procollagen N-proteinase ADAMTS-2. Biochem J 398: 515-519.
7. Stetler-Stevenson WG, (2008) Tissue inhibitors of metalloproteinases in cell signaling: metalloproteinase-independent biological activities. Sci Signal 1: re6.
8. Qi JH, Ebrahem Q, Moore N, Murphy G, Claesson-Welsh L, et al. (2003) A novel function for tissue inhibitor of metalloproteinases-3 (TIMP3): inhibition of angiogenesis by blockage of VEGF binding to VEGF receptor-2. Nat Med 9: 407-415.
9. Williamson RA, Marston FA, Angal S, Koklitis P, Panico M, et al. (1990) Disulphide bond assignment in human tissue inhibitor of metalloproteinases (TIMP). Biochem J 268: 267-274.
10. Brew K, Nagase H, (2010) The tissue inhibitors of metalloproteinases (TIMPs): an ancient family with structural and functional diversity. Biochim Biophys Acta 1803: 55-71.
11. Qi JH, Ebrahem Q, Yeow K, Edwards DR, Fox PL, et al. (2002) Expression of Sorsby's fundus dystrophy mutations in human retinal pigment Epithelial cells reduces matrix metalloproteinase inhibition and may promote angiogenesis. J Biol Chem 30: 30.
12. Apte SS, Olsen B, Murphy G, (1995) The gene structure of tissue inhibitor of metalloproteinases (TIMP)-3 and its inhibitory activities define the distinct TIMP gene family. J Biol Chem 270: 14313-14318.
13. Lee MH, Knauper V, Becherer JD, Murphy G, (2001) Full-length and N-TIMP-3 display equal inhibitory activities toward TNF-alpha convertase. Biochem Biophys Res Commun 280: 945-950.
14. Tobe T, Ortega S, Luna JD, Ozaki H, Okamoto N, et al. (1998) Targeted disruption of the FGF2 gene does not prevent choroidal neovascularization in a murine model. Am J Pathol 153: 1641-1646.
15. Lee MH, Atkinson S, Murphy G, (2007) Identification of the extracellular matrix (ECM) binding motifs of tissue inhibitor of metalloproteinases (TIMP)-3 and effective transfer to TIMP-1. J Biol Chem 282: 6887-6898.
16. Carmeliet P, Moons L, Luttun A, Vincenti V, Compernolle V, et al. (2001) Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat Med 7: 575-583.
17. Bussolati B, Dunk C, Grohman M, Kontos CD, Mason J, et al. (2001) Vascular endothelial growth factor receptor-1 modulates vascular endothelial growth factor-mediated angiogenesis via nitric oxide. Am J Pathol 159: 993-1008.
18. Qi JH, Dai G, Luthert P, Chaurasia S, Hollyfield J, et al. (2009) S156C-mutation in tissue inhibitor of metalloproteinases-3 induces increased angiogenesis. J Biol Chem.
19. Page-McCaw A, (2008) Remodeling the model organism: matrix metalloproteinase functions in invertebrates. Semin Cell Dev Biol 19: 14-23.
20. Gialeli C, Theocharis AD, Karamanos NK, (2011) Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting. Febs J 278: 16-27.
21. Fernandez CA, Butterfield C, Jackson G, Moses MA (2003) Structural and functional uncoupling of the enzymatic and angiogenic inhibitory activities of tissue inhibitor of metalloproteinase-2 (TIMP-2): loop 6 is a novel angiogenesis inhibitor. J Biol Chem 278: 40989-40995. Epub 42003 Aug 40984.
22. Seo DW, Li H, Guedez L, Wingfield PT, Diaz T, et al. (2003) TIMP-2 mediated inhibition of angiogenesis: an MMP-independent mechanism. Cell 114: 171-180.
23. Bodden MK, Harber GJ, Birkedal-Hansen B, Windsor LJ, Caterina NC, et al. (1994) Functional domains of human TIMP-1 (tissue inhibitor of metalloproteinases). J Biol Chem 269: 18943-18952.
24. Sorsby A, Joll Mason ME (1949) A fundus dystrophy with unusual features. British journal of Ophthalmology: 67-97.
25. Della NG, Campochiaro PA, Zack DJ, (1996) Localization of TIMP-3 mRNA expression to the retinal pigment epithelium. Invest Ophthalmol Vis Sci 37: 1921-1924.
26. Holz FG, Haimovici R, Wagner DG, Bird AC, (1994) Recurrent choroidal neovascularization after laser photocoagulation in Sorsby's fundus dystrophy. Retina 14: 329-334.
27. Jacobson SG, Cideciyan AV, Regunath G, Rodriguez FJ, Vandenburgh K, et al. (1995) Night blindness in Sorsby's fundus dystrophy reversed by vitamin A. Nat Genet. 11: 27-32.
28. Kalmus H, Seedburgh D, (1976) Probable common origin of a hereditary fundus dystrophy (Sorsby's familial pseudoinflammatory macular dystrophy) in an English and Australian family. J Med Genet 13: 271-276.
29. Polkinghorne PJ, Capon MR, Berninger T, Lyness AL, Sehmi K, et al. (1989) Sorsby's fundus dystrophy. A clinical study. Ophthalmology 96: 1763-1768.
30. Barbazetto IA, Hayashi M, Klais CM, Yannuzzi LA, Allikmets R, (2005) A novel TIMP3 mutation associated with Sorsby fundus dystrophy. Arch Ophthalmol 123: 542-543.
31. Felbor U, Benkwitz C, Klein ML, Greenberg J, Gregory CY, et al. (1997) Sorsby fundus dystrophy: reevaluation of variable expressivity in patients carrying a TIMP3 founder mutation. Arch Ophthalmol 115: 1569-1571.
32. Felbor U, Stohr H, Amann T, Schonherr U, Weber BH, (1995) A novel Ser156Cys mutation in the tissue inhibitor of metalloproteinases-3 (TIMP3) in Sorsby's fundus dystrophy with unusual clinical features. Hum Mol Genet 4: 2415-2416.
33. Langton KP, Barker MD, McKie N, (1998) Localization of the functional domains of human tissue inhibitor of metalloproteinases-3 and the effects of a Sorsby's fundus dystrophy mutation. J Biol Chem 273: 16778-16781.
34. Langton KP, McKie N, Curtis A, Goodship JA, Bond PM, et al. (2000) A novel tissue inhibitor of metalloproteinases-3 mutation reveals a common molecular phenotype in Sorsby's fundus dystrophy. J Biol Chem 275: 27027-27031.
35. Lin RJ, Blumenkranz MS, Binkley J, Wu K, Vollrath D, (2006) A novel His158Arg mutation in TIMP3 causes a late-onset form of Sorsby fundus dystrophy. Am J Ophthalmol 142: 839-848.
36. Tabata Y, Isashiki Y, Kamimura K, Nakao K, Ohba N, (1998) A novel splice site mutation in the tissue inhibitor of the metalloproteinases-3 gene in Sorsby's fundus dystrophy with unusual clinical features. Hum Genet 103: 179-182.
37. Weber BH, Vogt G, Pruett RC, Stohr H, Felbor U, (1994) Mutations in the tissue inhibitor of metalloproteinase-3 (TIMP-3) in patients with Sorsby's fundus dystrophy. Nature Genetics 8: 352-356.
38. Ebrahem Q, Qi JH, Sugimoto M, Ali M, Sears J, et al. (2011) Increased neovascularization in mice lacking tissue inhibitor of metalloproteinases-3. Invest Ophthalmol Vis Sci.
39. Amaral J, Becerra SP, (2010) Effects of human recombinant PEDF protein and PEDF-derived peptide 34-mer on choroidal neovascularization. Invest Ophthalmol Vis Sci 51: 1318-1326.
40. Saint-Geniez M, Maharaj AS, Walshe TE, Tucker BA, Sekiyama E, et al. (2008) Endogenous VEGF is required for visual function: evidence for a survival role on muller cells and photoreceptors. PLoS ONE 3: e3554.
41. Smith G, McLeod D, Foreman D, Boulton M, (1999) Immunolocalisation of the VEGF receptors FLT-1, KDR, and FLT-4 in diabetic retinopathy. Br J Ophthalmol 83: 486-494.